التداخل بين ديكلوفيناك وميزوبروستول وهيدروكورتيزون

Concurrent administration of corticosteroids with non-steroidal anti-inflammatory drugs (NSAIDS) may increase the risk of gastrointestinal adverse reactions.

Monitor patients receiving corticosteroids and concomitant NSAIDS for gastrointestinal adverse reactions [see Drug Interactions ( 7 )] .

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Clinical Impact: Concomitant use of NSAIDs and corticosteroids increases the risk of gastrointestinal adverse reactions.

Intervention: Monitor patients receiving ALKINDI SPRINKLE and concomitant NSAIDs.

NSAIDs: concomitant administration increases risk of gastrointestinal adverse reactions.

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status.

Corticosteroids Clinical Impact: Concomitant use of corticosteroids with diclofenac may increase the risk of GI ulceration or bleeding.

Intervention Monitor patients with concomitant use of diclofenac sodium/misoprostol with corticosteroids for signs of bleeding [see Warnings and Precautions (5.3) ] .